JMJD2B Inhibitors

The chemical class of "JMJD2B Inhibitors" encompasses a diverse group of compounds that interfere with the function of the JMJD2B protein. These inhibitors function through various mechanisms, such as directly binding to the active site of JMJD2B, mimicking crucial co-substrates or cofactors, or modulating related cellular pathways that indirectly affect JMJD2B's activity. A significant portion of these inhibitors, like GSK-J1, GSK-J4, and JIB-04, act by directly binding to the active site of JMJD2B. This binding prevents the enzyme from interacting with its natural substrates, thus inhibiting its demethylase activity. These inhibitors are particularly crucial as they target the catalytic domain of JMJD2B, rendering it inactive.

Other inhibitors operate by influencing the cellular environment or pathways connected to JMJD2B's function. For instance, Tranylcypromine, although primarily a monoamine oxidase inhibitor, affects the transcriptional regulation and chromatin remodeling processes, indirectly impacting JMJD2B activity. Similarly, Dimethyl fumarate and L-Ascorbic acid modulate cellular signaling pathways, which in turn can lead to the inhibition of JMJD2B's activity. Inhibitors like 2,4-Pyridinedicarboxylic acid and N-oxalylglycine function by mimicking the 2-oxoglutarate molecule, a co-substrate essential for JMJD2B's activity. By occupying the 2-oxoglutarate binding site, they prevent the enzyme from performing its normal function. Additionally, compounds such as Deferiprone exert their inhibitory effect by chelating essential metal ions, particularly iron, which is a critical cofactor for JMJD2B's enzymatic activity.